Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 184

Sort by

Sort Order Select

Journal Articles

JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results

Blood (2024) 144 (22): 2295–2307.

https://doi.org/10.1182/blood.2024024789

Published: 2024

Includes: Supplemental data

Journal Articles

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 1048.

https://doi.org/10.1182/blood-2024-210830

Published: 2024

Journal Articles

Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation

Blood (2024) 144 (Supplement 1): 4826.

https://doi.org/10.1182/blood-2024-202363

Published: 2024

Journal Articles

Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis

Blood (2024) 144 (Supplement 1): 4871.

https://doi.org/10.1182/blood-2024-208229

Published: 2024

Journal Articles

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Blood (2024) 144 (Supplement 1): 2071.

https://doi.org/10.1182/blood-2024-208021

Published: 2024

Journal Articles

Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide

Blood (2024) 144 (Supplement 1): 2130.

https://doi.org/10.1182/blood-2024-209164

Published: 2024

Journal Articles

JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results

Joseph Pidala, Shernan G. Holtan, Kelly Walton, Jongphil Kim, Hany Elmariah, Asmita Mishra, Nelli Bejanyan, Taiga Nishihori, Farhad Khimani, Lia Perez, Rawan Faramand, Marco Davila, Claudio Anasetti, Daniel Weisdorf, Bruce R Blazar, Jeffrey S Miller, Veronika Bachanova, Najla H El Jurdi, Brian C Betts

Blood (2023) 142 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2023-173376

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide Equalizes Clinical Outcomes of Allogeneic Hematopoietic Cell Transplantation across Racial and Ethnic Populations

Teresa Caprice, Wenyi Fan, Jongphil Kim, Rawan Faramand, Asmita Mishra, Lia Perez, Farhad Khimani, Aleksandr Lazaryan, Jose L. Ochoa-Bayona, Hien Liu, Michael D. Jain, Michael Nieder, Claudio Anasetti, Taiga Nishihori, Joseph A. Pidala, Nelli Bejanyan, Hany Elmariah

Blood (2023) 142 (Supplement 1): 390.

https://doi.org/10.1182/blood-2023-186738

Published: 2023

Journal Articles

Phase I Trial of Allogeneic Donor Gamma Delta T Cell Infusion Post-Hematopoietic Cell Transplantation, an Interim Safety Report

Nelli Bejanyan, Hany Elmariah, Kayla Reid, Bin Yu, Jongphil Kim, Cheryl Cox, Melissa Lowden, Rawan Faramand, Christopher Cubitt, Hien Liu, Justin Boucher, Jose Alejandro Guevara, David A Sallman, Jeffrey Lancet, Joseph A. Pidala, Kumar Karyampudi, Frederick L. Locke, Claudio Anasetti, Marco Davila

Blood (2023) 142 (Supplement 1): 4846.

https://doi.org/10.1182/blood-2023-187058

Published: 2023

Journal Articles

Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant

Hany Elmariah, Jongphil Kim, Asmita Mishra, Rawan Faramand, Lia Perez, Aleksandr Lazaryan, Farhad Khimani, Hien Liu, Jose L. Ochoa-Bayona, Michael Nieder, Nicholas Figura, Timothy J Robinson, Taiga Nishihori, Claudio Anasetti, Joseph A. Pidala, Nelli Bejanyan

Blood (2023) 142 (Supplement 1): 4900.

https://doi.org/10.1182/blood-2023-187473

Published: 2023

Journal Articles

Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant Outcomes for Acute Myeloid Leukemia

Omar Albanyan, Syeda Mahrukh Hussnain Naqvi, Qianxing Mo, Athena Belfon, Eric Gaskill, Taiga Nishihori, Rawan Faramand, Aleksandr Lazaryan, Doris K. Hansen, Farhad Khimani, Asmita Mishra, Michael Nieder, Lia Perez, Hien D. Liu, Joseph Pidala, Claudio Anasetti, Frederick L. Locke, Nelli Bejanyan, Hany Elmariah

Blood (2022) 140 (Supplement 1): 7664–7666.

https://doi.org/10.1182/blood-2022-166008

Published: 2022

Journal Articles

Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Blood (2022) 140 (Supplement 1): 886–888.

https://doi.org/10.1182/blood-2022-168175

Published: 2022

Journal Articles

Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Blood (2022) 140 (Supplement 1): 7638–7640.

https://doi.org/10.1182/blood-2022-168400

Published: 2022

Journal Articles

The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Rdsafe and BMT CTN 0201

Nosha Farhadfar, Stephanie Bo-Subait, Kwang Woo Ahn, Brent R. Logan, Heather E. Stefanski, Jack W. Hsu, Sandhya R. Panch, Dennis L. Confer, Claudio Anasetti, Michael A. Pulsipher, Bronwen E. Shaw, John R. Wingard, Galen E. Switzer

Blood (2021) 138 (Supplement 1): 1772.

https://doi.org/10.1182/blood-2021-151034

Published: 2021

Journal Articles

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

Blood (2021) 137 (19): 2621–2633.

https://doi.org/10.1182/blood.2020007445

Published: 2021

Includes: Supplemental data

Journal Articles

Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients

Giacomo Adoncecchi, MS, Ambuj Kumar, MD MPH, Rawan Faramand, MD, Hien D. Liu, MD, Farhad Khimani, MD, Asmita Mishra, MD, Michael Nieder, MD, Taiga Nishihori, MD, Lia Perez, MD, Joseph Pidala, MD, Claudio Anasetti, MD, Nelli Bejanyan, MD, Hany Elmariah, MDMS

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-141966

Published: 2020

Journal Articles

Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Salman Otoukesh, MD, Hany Elmariah, MDMS, Dongyun Yang, PhD, Sally Mokhtari, PhD, Madiha Siraj, Haris Ali, MD, Krishnakar Mogili, Shukaib Arslan, MD, Taiga Nishihori, MD, Chatchada Karanes, MD, Joseph Pidala, MD, Ryotaro Nakamura, MD, Claudio Anasetti, MD, Stephen J. Forman, MD, Monzr M. Al Malki, MD, Nelli Bejanyan, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-143166

Published: 2020

Journal Articles

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-137677

Published: 2020

Journal Articles

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Joseph Pidala, MD, Kelly Walton, Hany Elmariah, MDMS, Jongphil Kim, PhD, Asmita Mishra, MD, Nelli Bejanyan, MD, Taiga Nishihori, MD, Farhad Khimani, MBBS, Lia Perez, MD, Rawan Faramand, MD, Marco L. Davila, MD PhD, Michael Nieder, MD, Nicholas Lawrence, PhD, Harshani Lawrence, PhD, Claudio Anasetti, MD, Said Sebti, PhD, Brian C. Betts, MD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-133874

Published: 2020

Journal Articles

Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel

Ariel Perez Perez, MD, Christina A Bachmeier, PharmD, Renee Smilee, Albert J Ribickas, Aleksandr Lazaryan, MDPhDMPH, Julio C. Chavez, MD, Claudio Anasetti, MD, Bijal Shah, MD, Farhad Khimani, MBBS, Taiga Nishihori, MD, Marco L. Davila, MD PhD, Frederick L. Locke, MD, Michael D. Jain, MDPhD, Hien D. Liu, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-143336

Published: 2020

NARROW

JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation

Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide

JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results

Post-Transplant Cyclophosphamide Equalizes Clinical Outcomes of Allogeneic Hematopoietic Cell Transplantation across Racial and Ethnic Populations

Phase I Trial of Allogeneic Donor Gamma Delta T Cell Infusion Post-Hematopoietic Cell Transplantation, an Interim Safety Report

Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant

Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant Outcomes for Acute Myeloid Leukemia

Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Rdsafe and BMT CTN 0201

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients

Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only